Entertainment
CORXEL And LENZ Therapeutics Announce Positive Topline Data From China Phase 3 Presbyopia Trial Of LNZ100
(MENAFN - GlobeNewsWire - Nasdaq) Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment,and maintaining their ...
By: menafn
- Oct 28 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS